Roche Holdings Ltd ADR (RHHBY)

$40.16 -1.16 (-2.81%)
Market Cap 263.54B
Revenue (ttm) 70.87B
Net Income (ttm) 9.40B
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 14.40
Profit Margin 13.27%
Debt to Equity Ratio 0.96
Volume 995,600
Avg Vol 1,987,220
Day's Range N/A - N/A
Shares Out 6.38B
Stochastic %K 5%
Beta 0.46
Analysts Sell
Price Target $44.62

Company Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19,...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 41 61 688 88 80
Fax: 41 61 691 00 14
Address:
Grenzacherstrasse 124, Basel, Switzerland
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jun. 17 at 4:36 AM
$LMDX $RHHBY $SPY $NDAQ #BillGates quoted…. “One example is the inexpensive LumiraDx portable testing system, which health workers can bring to remote communities and obtain highly accurate results within just 12 minutes.” • From a Gates Foundation article stressing its global health impact  . The Gates Foundation invested over $50 million into LumiraDx to deliver affordable, life-saving diagnostics to the world’s most vulnerable. That mission was enabled by shareholders who funded the platform’s development, global expansion, and infrastructure. Yet when the IP was transferred and the company dissolved, those same shareholders received nothing. If the impact is real—and the value undeniable—then so is the injustice of excluding the very people who helped finance it.
1 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jun. 17 at 4:27 AM
$LMDX $NDAQ $RHHBY $SPY THEY CONTROLLED THE VOTE… IT WAS ALL ORCHESTRATED SO WELL.. UNTILL IT WAS EXPOSED 🚨🚨🚨🚨🚨🚨🚨🚨🚨 If Ameye were truly independent, she would have disclosed her Javi ties and recused herself. Instead, she signed off as the final assets disappeared. The conflict wasn’t removed. It was embedded—and executed through insiders in plain sight.
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jun. 17 at 4:26 AM
$LMDX $RHHBY $SPY $NDAQ One of my favorites—because it exposes how full of it they really are. 🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨 Ron Zwanziger and the other LumiraDx founders claimed they resigned to “avoid conflicts of interest” as major shareholders and to “preserve flexibility.” But they didn’t hand control to an independent party—they handed it to Veronique Ameye, their long-time insider. Ameye had been Deputy CEO, General Counsel, and later became CEO just as the company collapsed. She was also director of Javi Ventures Ltd since 2016—never disclosed to public investors—while overseeing the liquidation, Roche sale, and transfer of key IP. Shareholders got nothing. Insiders? Bonuses, jobs, and control. They didn’t step aside to protect transparency. They stepped aside to keep control without being accountable. This was not about avoiding conflicts—it was about managing the optics while executing a controlled demolition. Bonuses? Paid. IP? Stripped. Leadership? Handpicked. Shareholders? Wiped out.
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jun. 17 at 4:08 AM
$SPY $RHHBY $LMDX $NDAQ Matt Sause (July 29th 2024) “Access to diagnostic testing is critical for the delivery of healthcare worldwide and we are confident that the LumiraDx platform and technology will help us expand the availability of testing, especially in settings such as primary care and low and middle income countries.” 🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨 Side Note for Shareholders: On July 29, Roche finalized its takeover of LumiraDx’s platform—including the TB diagnostic, NT-proBNP, and dozens of core patents—without paying a single cent to shareholders. This quote marks the moment they publicly claimed the fruits of our investments, including assets funded by the Gates Foundation and retail investors alike. No shareholder vote. No final report. No accountability. Just a silent transfer of world-changing IP into Roche’s hands—on the backs of those who built it.
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jun. 17 at 4:02 AM
$RHHBY $LMDX Matt Sause Also States “LumiraDx has developed a highly versatile platform that delivers strong performance across multiple disease areas and technologies. We believe this will enable better patient access to timely results in decentralised healthcare settings worldwide.” Goes well with the rapid testing Matt… wouldn’t you agree? Imagine this… This “highly versatile platform” was developed with over $1 billion in shareholder and public funding, including support from institutions like the Gates Foundation. Yet when Roche acquired it, no compensation was provided to the very investors who financed its creation. The value continues—just not for those who paid for it.
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jun. 17 at 3:57 AM
$RHHBY $LMDX Matt Sause, CEO of Roche Diagnostics • At signing (Dec 29, 2023): “The addition of the LumiraDx technology to our diagnostics portfolio will enable us to transform testing at the point of care.” Point-of-care diagnostics alone contribute approximately $35–40 billion per year, with growth fueled by rapid testing (lmdx) innovations and global health initiatives. Don’t forget the TB Matt.
0 · Reply
StocktwitsNews
StocktwitsNews Jun. 17 at 2:37 AM
Roche Stock Slides After Failed Blood Cancer Trial With AbbVie, But Parkinson’s Therapy Progress Boosts Retail Mood $RHHBY $ABBV https://stocktwits.com/news/equity/markets/roche-stock-slides-after-failed-blood-cancer-trial-with-abb-vie-but-parkinson-s-therapy-progress-boosts-retail-mood/chlY10aRRTP
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jun. 17 at 2:24 AM
$LMDX $RHHBY $NDAQ $SPY 🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨 #SEC #SECgov To Fellow LumiraDx Shareholders, Under the control of Ron Zwanziger and Veronique Ameye, LumiraDx was dismantled and stripped of its value—while we, the shareholders, were left with nothing. We were told Roche acquired “select assets.” That was a lie. Liquidation records confirm Roche took the majority of subsidiaries and all trademarks. No vote. No final report. No payout. Gone with it: Shareholder/ Gates Foundation invesments – TB diagnostic (US20230293068A1), now in Roche’s hands. That one patent alone could be worth BILLIONS 💵 . Also gone: NT-proBNP, respiratory platforms, and over 40 patent families developed across LumiraDx, SureSensors, and Invita—funded by us. As LumiraDx collapsed, insiders resigned—then reappeared at ElectraDx and SureSensors, now holding the same IP and staff we paid for. WHERES INVITA? The Valuable IP lives on. It was taken—deliberately. This wasn’t a wind-down. It was an insider-led hijacking.
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jun. 17 at 1:13 AM
$LMDX $RHHBY #ShareholderRights #LumiraDx #Roche #GatesFoundation #EndTB #IPTheft #CorporateAccountability #FraudAlert @BillGates #BillGates SEND IT TO X LumiraDx shareholders were cut out of a multi-billion-dollar TB diagnostic platform—funded by investors and backed by a $14M Gates Foundation grant. We Trusted This! The IP was stripped, transferred, and absorbed—while insiders were rewarded and shareholders got nothing. Roche now holds the technology. We carried the risk. There was no compensation. No transparency. No justice. Theft.. plan and simple PAY THE LUMIRADX SHAREHOLDERS
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jun. 17 at 1:03 AM
$LMDX $RHHBY “constructive fraudulent transfer” 🚨🚨🚨⏰⏰⏰🚨🚨🚨 You took a multi-billion-dollar TB platform funded by investor capital—don’t pretend this was some worthless asset. We know what it’s worth. If you’re unsure how much to pay LumiraDx shareholders, let the comps help you out: GenMark sold for $1.8B. Cepheid went for $4B. Alere—$5.3B. Each had diagnostic IP portfolios comparable to what you now control. You didn’t just buy a Point-of-Care device. You took the engine—every assay, every cartridge, every patent, including the TB platform that could change the world. That IP wasn’t worthless, and neither are the shareholders who funded it. Insiders already got theirs—bonuses, jobs, stock options. Leave them out of this payout. It looks like they have been cooking the books and shifting assets for years.
0 · Reply
Latest News on RHHBY
No data available.
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jun. 17 at 4:36 AM
$LMDX $RHHBY $SPY $NDAQ #BillGates quoted…. “One example is the inexpensive LumiraDx portable testing system, which health workers can bring to remote communities and obtain highly accurate results within just 12 minutes.” • From a Gates Foundation article stressing its global health impact  . The Gates Foundation invested over $50 million into LumiraDx to deliver affordable, life-saving diagnostics to the world’s most vulnerable. That mission was enabled by shareholders who funded the platform’s development, global expansion, and infrastructure. Yet when the IP was transferred and the company dissolved, those same shareholders received nothing. If the impact is real—and the value undeniable—then so is the injustice of excluding the very people who helped finance it.
1 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jun. 17 at 4:27 AM
$LMDX $NDAQ $RHHBY $SPY THEY CONTROLLED THE VOTE… IT WAS ALL ORCHESTRATED SO WELL.. UNTILL IT WAS EXPOSED 🚨🚨🚨🚨🚨🚨🚨🚨🚨 If Ameye were truly independent, she would have disclosed her Javi ties and recused herself. Instead, she signed off as the final assets disappeared. The conflict wasn’t removed. It was embedded—and executed through insiders in plain sight.
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jun. 17 at 4:26 AM
$LMDX $RHHBY $SPY $NDAQ One of my favorites—because it exposes how full of it they really are. 🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨 Ron Zwanziger and the other LumiraDx founders claimed they resigned to “avoid conflicts of interest” as major shareholders and to “preserve flexibility.” But they didn’t hand control to an independent party—they handed it to Veronique Ameye, their long-time insider. Ameye had been Deputy CEO, General Counsel, and later became CEO just as the company collapsed. She was also director of Javi Ventures Ltd since 2016—never disclosed to public investors—while overseeing the liquidation, Roche sale, and transfer of key IP. Shareholders got nothing. Insiders? Bonuses, jobs, and control. They didn’t step aside to protect transparency. They stepped aside to keep control without being accountable. This was not about avoiding conflicts—it was about managing the optics while executing a controlled demolition. Bonuses? Paid. IP? Stripped. Leadership? Handpicked. Shareholders? Wiped out.
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jun. 17 at 4:08 AM
$SPY $RHHBY $LMDX $NDAQ Matt Sause (July 29th 2024) “Access to diagnostic testing is critical for the delivery of healthcare worldwide and we are confident that the LumiraDx platform and technology will help us expand the availability of testing, especially in settings such as primary care and low and middle income countries.” 🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨 Side Note for Shareholders: On July 29, Roche finalized its takeover of LumiraDx’s platform—including the TB diagnostic, NT-proBNP, and dozens of core patents—without paying a single cent to shareholders. This quote marks the moment they publicly claimed the fruits of our investments, including assets funded by the Gates Foundation and retail investors alike. No shareholder vote. No final report. No accountability. Just a silent transfer of world-changing IP into Roche’s hands—on the backs of those who built it.
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jun. 17 at 4:02 AM
$RHHBY $LMDX Matt Sause Also States “LumiraDx has developed a highly versatile platform that delivers strong performance across multiple disease areas and technologies. We believe this will enable better patient access to timely results in decentralised healthcare settings worldwide.” Goes well with the rapid testing Matt… wouldn’t you agree? Imagine this… This “highly versatile platform” was developed with over $1 billion in shareholder and public funding, including support from institutions like the Gates Foundation. Yet when Roche acquired it, no compensation was provided to the very investors who financed its creation. The value continues—just not for those who paid for it.
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jun. 17 at 3:57 AM
$RHHBY $LMDX Matt Sause, CEO of Roche Diagnostics • At signing (Dec 29, 2023): “The addition of the LumiraDx technology to our diagnostics portfolio will enable us to transform testing at the point of care.” Point-of-care diagnostics alone contribute approximately $35–40 billion per year, with growth fueled by rapid testing (lmdx) innovations and global health initiatives. Don’t forget the TB Matt.
0 · Reply
StocktwitsNews
StocktwitsNews Jun. 17 at 2:37 AM
Roche Stock Slides After Failed Blood Cancer Trial With AbbVie, But Parkinson’s Therapy Progress Boosts Retail Mood $RHHBY $ABBV https://stocktwits.com/news/equity/markets/roche-stock-slides-after-failed-blood-cancer-trial-with-abb-vie-but-parkinson-s-therapy-progress-boosts-retail-mood/chlY10aRRTP
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jun. 17 at 2:24 AM
$LMDX $RHHBY $NDAQ $SPY 🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨 #SEC #SECgov To Fellow LumiraDx Shareholders, Under the control of Ron Zwanziger and Veronique Ameye, LumiraDx was dismantled and stripped of its value—while we, the shareholders, were left with nothing. We were told Roche acquired “select assets.” That was a lie. Liquidation records confirm Roche took the majority of subsidiaries and all trademarks. No vote. No final report. No payout. Gone with it: Shareholder/ Gates Foundation invesments – TB diagnostic (US20230293068A1), now in Roche’s hands. That one patent alone could be worth BILLIONS 💵 . Also gone: NT-proBNP, respiratory platforms, and over 40 patent families developed across LumiraDx, SureSensors, and Invita—funded by us. As LumiraDx collapsed, insiders resigned—then reappeared at ElectraDx and SureSensors, now holding the same IP and staff we paid for. WHERES INVITA? The Valuable IP lives on. It was taken—deliberately. This wasn’t a wind-down. It was an insider-led hijacking.
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jun. 17 at 1:13 AM
$LMDX $RHHBY #ShareholderRights #LumiraDx #Roche #GatesFoundation #EndTB #IPTheft #CorporateAccountability #FraudAlert @BillGates #BillGates SEND IT TO X LumiraDx shareholders were cut out of a multi-billion-dollar TB diagnostic platform—funded by investors and backed by a $14M Gates Foundation grant. We Trusted This! The IP was stripped, transferred, and absorbed—while insiders were rewarded and shareholders got nothing. Roche now holds the technology. We carried the risk. There was no compensation. No transparency. No justice. Theft.. plan and simple PAY THE LUMIRADX SHAREHOLDERS
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jun. 17 at 1:03 AM
$LMDX $RHHBY “constructive fraudulent transfer” 🚨🚨🚨⏰⏰⏰🚨🚨🚨 You took a multi-billion-dollar TB platform funded by investor capital—don’t pretend this was some worthless asset. We know what it’s worth. If you’re unsure how much to pay LumiraDx shareholders, let the comps help you out: GenMark sold for $1.8B. Cepheid went for $4B. Alere—$5.3B. Each had diagnostic IP portfolios comparable to what you now control. You didn’t just buy a Point-of-Care device. You took the engine—every assay, every cartridge, every patent, including the TB platform that could change the world. That IP wasn’t worthless, and neither are the shareholders who funded it. Insiders already got theirs—bonuses, jobs, stock options. Leave them out of this payout. It looks like they have been cooking the books and shifting assets for years.
0 · Reply
LewisDaKat
LewisDaKat Jun. 17 at 12:55 AM
News Genentech to Advance Prasinezumab Into Phase III Development for Early-Stage Parkinson's Disease https://marketwirenews.com/news-releases/genentech-to-advance-prasinezumab-into-phase-iii-dev-5659651795797209.html $RHHBY
0 · Reply
clan
clan Jun. 16 at 8:58 PM
MNKD-101 nears. If just 25% of the total market is captured, with a 70% Profit Margin and conservatively a 20 PE, this adds $24/sh to $MNKD . CLOFAZIMINE (CIS) by Mannkind ----------------------------------------------------- Designations: - Phase 3 ICoN-1 trial - Fast Tracked by FDA - Orpan Drug - Qualified Infectious Disease Product - Well tolerated - No significant Adverse Events - Localized treatment (lungs) - Improved patient adherence - Indications for arthritis & CANCERs - Current global mkt $2.1B [2023] ...and coming soon..... - - - Clofazimine DPI No red skin (or green). Partner with $GSK ? $NVS ? $RHHBY ?
2 · Reply
ImYourPhuckleberry
ImYourPhuckleberry Jun. 16 at 8:21 PM
$LMDX $RHHBY Halfway through June. Tick tock.
0 · Reply
Dww0311
Dww0311 Jun. 16 at 4:54 PM
$RHHBY $LMDX That’s what happens when a company goes into insolvency and secured creditors hold liens for more than the total value of the assets. Neither Roche nor anyone else owes you a dime. The company told you point blank in late December 2023, and arguably earlier than that as well, that its shareholders would be wiped out. You either chose not to listen or you chose to ignore that in favor of believing in fantasies. Welcome to reality.
0 · Reply
ZacksResearch
ZacksResearch Jun. 16 at 3:59 PM
$RHHBY advances prasinezumab to phase III—could this be a game changer for Parkinson’s? 🧠 After showing positive trends at 104 weeks in the phase IIb PADOVA study, even though it missed statistical significance, Roche believes in prasinezumab’s potential as the first disease-modifying treatment for Parkinson’s disease. Despite missing the primary endpoint, the candidate's long-term benefits look promising. Discover the full details and implications here 👉 https://www.zacks.com/commentary/2503466/rhhby-to-advance-parkinsons-disease-drug-to-late-stage-development?cid=sm-stocktwits-2-2503466-body&ADID=SYND_STOCKTWITS_TWEET_2_2503466_BODY
0 · Reply
BiotechBonesaw
BiotechBonesaw Jun. 16 at 3:32 PM
$PPBT CM24 & NT-219 are game changers… when will $BMY or $MRK sign a deal to extend their Immunooncology dominance? $RHHBY could use a win too after the unfortunate setback in DMD by Sarepta $SRPT
0 · Reply
ZacksResearch
ZacksResearch Jun. 16 at 1:03 PM
$RHHBY pushing into late-stage Parkinson’s trial — could be a game changer 🧠⚡️ Roche is advancing prasinezumab to phase III, aiming for a first-in-class disease-modifying therapy for early Parkinson’s. Full breakdown on the move and what’s next 👉 https://www.zacks.com/stock/news/2503466/rhhby-to-advance-parkinsons-disease-drug-to-late-stage-development?cid=sm-stocktwits-2-2503466-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2503466_TEASER
0 · Reply
DonCorleone77
DonCorleone77 Jun. 16 at 10:07 AM
$RHHBY Genentech to proceed with Phase III development of prasinezumab Genentech, a member of Roche (RHHBY), announced its decision to proceed with Phase III development of prasinezumab, an investigational anti-alpha-synuclein antibody, in early-stage Parkinson's disease. This decision is informed by data from the Phase IIb PADOVA study and ongoing open-label extensions of PADOVA and Phase II PASADENA studies. Multiple endpoints from the PADOVA and OLE studies suggest a potential clinical benefit of prasinezumab when added to effective symptomatic treatment in early-stage Parkinson's disease. Prasinezumab showed potential clinical efficacy in the primary endpoint of time to confirmed motor progression, although missed statistical significance. Positive trends towards reduced motor progression at 104 weeks were observed; these effects appear to be sustained over longer treatment periods based on additional OLE data. The PADOVA study also provided the first biomarker evidence of prasinezumab impacting the underlying disease biology. The PASADENA and PADOVA OLE studies, which are evaluating the long-term safety and efficacy of prasinezumab in over 750 people with early-stage Parkinson's disease, are ongoing.
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jun. 16 at 1:36 AM
$LMDX $RHHBY Veronique — if LumiraDx is “now part of Roche,” as you’ve publicly stated, then the company is not dead. It has merely changed form. So why are shareholders being denied any residual value, disclosure, or remedy? “CEO and General Counsel of LumiraDx (now part of Roche Diagnostics). Responsible for directing the legal strategy, establishing global regulatory pathways, securing market access in key countries, and managing our global team of over 1,600 people.” Refers to LumiraDx as “now part of Roche”, implying a full integration rather than selective asset purchase.
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jun. 16 at 12:57 AM
$LMDX $RHHBY ‼️🚨🚨🚨🚨🚨🚨🚨🚨‼️ Why have LumiraDx’s top executives secured new roles and protections—while shareholders have been cast aside and silenced? Let’s be clear: Shareholders funded the development, launch, and global expansion of LumiraDx’s core diagnostic platform. Executives like Ron Zwanziger and Veronique Ameye orchestrated the public listing, the Roche deal, and the quiet dismantling of the company—all while ensuring their own continued control, compensation, or reappointment in successor entities. Now we find them in positions of power within Roche-related operations or spin-off companies built on the very IP shareholders once owned. Where is the accountability? Where is the transparency? And where is the shareholder compensation for the value that was extracted and transferred?
1 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jun. 15 at 8:56 PM
$LMDX $RHHBY This speaks volumes—your words confirm the truth. Now honor them, and give shareholders what is rightfully ours. “We” also believed in the Technology! “We are absolutely delighted to continue our journey as part of Roche Diagnostics. Being an integral part of the Roche network opens the door to realising the full potential of our Point of Care technology, and to increasing patient access to community-based healthcare around the world. We look forward to writing the next chapter in our shared efforts to deliver even greater impact for patients.”  Veronique Ameye held the dual role of Chief Executive Officer and General Counsel of LumiraDx at the time she made that statement on July 29, 2024 .
1 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jun. 15 at 7:46 PM
$LMDX $RHHBY I am writing to formally request clarification regarding the current status, ownership, and control of the intellectual property (IP) portfolio formerly held by FitLinxx, Inc., which was acquired by LumiraDx in 2016. Specifically, I am referring to the following patents and associated global filings: • US8795185B2 – Physiological sensor patch • US9238007B2 – Body-worn temperature monitoring • US9801566B2 – Biometric data interface • US9681866B2 – Wireless ECG patch • US9949813B2 – Method for calculating RR intervals • WO2014127046A1 / EP2788447B1 – Sensor patch with embedded power and remote monitoring capabilities
2 · Reply